What about new comers developing in situ strategies like Umoja, Interius, Sana, Tidal ?

Yes, there are several new companies developing in situ CAR-T (Chimeric Antigen Receptor T-cell) therapies. Some of the companies you mentioned, such as Umoja, Interius, Sana, and Tidal, are among the emerging players in this field.

These companies are pursuing innovative approaches to CAR-T therapy, with the goal of improving the efficacy and safety of these treatments. For example, Umoja is developing a platform for engineering CAR-T cells in the body, while Interius is developing a technology for controlling the activity of CAR-T cells in real-time.

These new companies are still in the early stages of development, and their technologies and therapies are still in the preclinical or early clinical stages of development. However, they hold great promise for the future of CAR-T therapy and the treatment of cancer, and are worth keeping an eye on as the field continues to evolve and mature.

In conclusion, the CAR-T field is rapidly evolving, and new companies like Umoja, Interius, Sana, and Tidal are among the emerging players in the development of in situ CAR-T therapies. These companies are pursuing innovative approaches to CAR-T therapy, and their work holds great promise for the future of cancer treatment.

‍